WuXi Biologics Partners with AstraZeneca for Local Production of Evusheld
China-based WuXi Biologics (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO), announced...
AstraZeneca
AstraZeneca’s H1 2022 Revenues Surge 48%, Led by Oncology and Vaccines
UK-based AstraZeneca (AZ, NASDAQ: AZN) released its financial report for H1 2022, showing a 48%...
Sihuan Pharma’s Xuanzhu Bio Files for Fulvestrant-Piroxetine Combo in Advanced Breast Cancer
China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) announced that the National Medical Products Administration...
HutchMed’s Orpathys-Tagrisso Combo Shows Promise in NSCLC at WCLC
China-based HutchMed (NASDAQ: HCM, HKG: 0013) announced the publication of an abstract detailing the SAVANNAH...
Dizal Pharma’s DZD1516 Receives NMPA Green Light for HER2+ Breast Cancer Trial
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192), spun out from AstraZeneca’s China drug discovery unit...
Organon’s China Head Shi Wang Departs to Lead Sanofi Greater China
Women’s health specialist Organon (NYSE: OGN) announced the departure of its former China unit head...
AstraZeneca Expands in China with Qingdao Partnership and Manufacturing Base
UK-based pharmaceutical giant AstraZeneca (NASDAQ: AZN) is significantly expanding its presence in China through a...
Jiangsu Hengrui Medicine’s SHR4640 Receives NMPA Approval for Gout Trial
China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced receiving approval from the National...